Medicine & Life Sciences
B-Cell Lymphoma
100%
Anaplastic Large-Cell Lymphoma
89%
Peripheral T-Cell Lymphoma
70%
Acute Myeloid Leukemia
68%
Lymphoma
54%
Chimeric Antigen Receptors
51%
ofatumumab
51%
Progression-Free Survival
50%
B-Cell Chronic Lymphocytic Leukemia
48%
Therapeutics
47%
Rituximab
46%
romidepsin
45%
Brentuximab Vedotin
44%
Multiple Myeloma
43%
T-Lymphocytes
42%
Neoplasms
40%
MLN 8237
38%
Mantle-Cell Lymphoma
37%
Survival
37%
axicabtagene ciloleucel
36%
Lymphoma, Large B-Cell, Diffuse
36%
T-Cell Lymphoma
35%
Hematologic Neoplasms
35%
Hodgkin Disease
33%
Aurora Kinase A
31%
Non-Hodgkin's Lymphoma
30%
Drug Therapy
30%
Breast Implants
29%
Cell- and Tissue-Based Therapy
28%
Bortezomib
26%
TAK-659
25%
Myeloid Cells
24%
Histone Deacetylase Inhibitors
24%
Allogeneic Cells
23%
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
23%
Follicular Lymphoma
23%
Apoptosis
22%
Transplants
22%
Leukemia
22%
Cyclophosphamide
22%
Hematopoietic Stem Cell Transplantation
21%
Stem Cells
21%
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
21%
fludarabine
21%
Lenalidomide
21%
Safety
20%
Stem Cell Transplantation
20%
Radiotherapy
20%
Pharmacokinetics
19%
pegaspargase
18%